P2.04-27 Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC
Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1251
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV